{"id":468313,"date":"2021-03-31T07:03:20","date_gmt":"2021-03-31T11:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=468313"},"modified":"2021-03-31T07:03:20","modified_gmt":"2021-03-31T11:03:20","slug":"provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/","title":{"rendered":"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>46% complete response of patients at Melanoma Institute Australia<\/li>\n<li>Fifth published study of in-transit melanoma lesion treatment with single-agent PV-10<\/li>\n<li>26-50% complete response (52-86% overall response) in these studies<\/li>\n<\/ul>\n<p align=\"justify\">KNOXVILLE, TN, March  31, 2021  (GLOBE NEWSWIRE) &#8212; Provectus (OTCQB: PVCT) today announced that <em>Melanoma Research<\/em> had published results from an investigator-led, single-center study of Australian in-transit melanoma (ITM) patients who received intralesional (aka intratumoral) PV-10 under a Provectus-sponsored expanded access (aka compassionate use) program (EAP).<\/p>\n<p align=\"justify\">The <em>Melanoma Research<\/em> article, entitled \u201cTreatment of in-transit melanoma metastases using intralesional PV-10,\u201d detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016.<\/p>\n<p>The article may be accessed at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g6OI9Do5RaMGa7aXzvXZHRfobM015YM5AM_4IOLdjZPk3p1x2UbtPom8M0ODKapxEADSgtc3WbCSjXogBPfcyBRfbTDxCo7zVvXqR61n1h-MQHbvtjIcbkD9I6jYObZkw9lbknEbeHAoKcljQ-OJ6Xi3Nu1BIikn-zgnSsgnKATZ7YAMsEZYZxgX64V42i0QiT-hdHty4e0x49q6UPnIHk9H-c5NAA4Q_k_5d2MilWJajcRZXuyY-B7JzSTVtgf9QauxchpGTOaEsKVjfr2Z5yjMbvOGLDFkC70cQW4CmhU2ZhxLFK6zkBfwmRB9EZqhZDVTDfyd3VU4i2ZzA21LJQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/journals.lww.com\/melanomaresearch\/Abstract\/9000\/Treatment_of_in_transit_melanoma_metastases_using.99046.aspx<\/u><\/a> (subscription required).<\/p>\n<p align=\"justify\">Key highlights of the <em>Melanoma Research<\/em> publication:<\/p>\n<ul type=\"disc\">\n<li>Baseline characteristics: 58% women; median age of 75.1 years (range 21.5-93.5),<\/li>\n<li>Median of 5 lesions treated with PV-10 (interquartile range [IQR] 2-7),<\/li>\n<li>Median of 1 PV-10 treatment (IQR 1-2),<\/li>\n<li>46% complete response (CR) and 86% overall response rate (ORR) in patients, and<\/li>\n<li>12- and 24-month overall survival (OS) rates of 77% and 56%, respectively.<\/li>\n<\/ul>\n<p align=\"justify\">This is the third publication about single-agent PV-10 treatment of ITM lesions under Provectus\u2019 EAP (which has treated about 200 patients to date) and the fifth publication overall. Previous publications describing EAPs led by other major Australian medical institutions and the Company\u2019s Phase 1 and 2 clinical trials at Australian and U.S. sites include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\u201cIntralesional PV-10 for the treatment of in-transit melanoma metastases \u2013 Results of a prospective, non-randomized, single center study\u201d (<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6668008\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Read et al. <\/u><em><u>J Surg Oncol<\/u><\/em><u> 2018<\/u><\/a>), which describes the EAP at Princess Alexandra Hospital in Brisbane: 45 patients treated from 2008 to 2015; 42% patient CR (86% ORR); median of 1 PV-10 treatment (range 1-4),<br \/>\u00a0<\/li>\n<li style=\"text-align:justify\">\u201cIntralesional PV-10 for in-transit melanoma \u2013 A single-center experience\u201d (<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/jso.24311\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Lippey et al. <\/u><em><u>J Surg Oncol<\/u><\/em><u> 2016<\/u><\/a>; subscription required), which describes the EAP at Peter MacCallum Cancer Centre in Melbourne: 19 patients treated from 2010 to 2014; 26% patient CR (52% ORR); most patients received 1 PV-10 treatment,<br \/>\u00a0<\/li>\n<li style=\"text-align:justify\">\u201cPhase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma\u201d (<a href=\"https:\/\/link.springer.com\/article\/10.1245\/s10434-014-4169-5\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Thompson et al. <\/u><em><u>Ann Surg Oncol<\/u><\/em><u> 2015<\/u><\/a>): 28 (out of 80) patients with all known lesions treated; median of 1 PV-10 treatment (range 1-4); 50% patient CR (71% ORR), and<br \/>\u00a0<\/li>\n<li style=\"text-align:justify\">\u201cChemoablation of metastatic melanoma using intralesional Rose Bengal\u201d (<a href=\"https:\/\/journals.lww.com\/melanomaresearch\/pages\/articleviewer.aspx?year=2008&amp;issue=12000&amp;article=00005&amp;type=abstract\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Thompson et al. <\/u><em><u>Mel Res<\/u><\/em><u> 2008<\/u><\/a>; subscription required): 11 (out of 20) patients treated in the Phase 1 trial; 1 PV-10 treatment; 27% patient CR (54% ORR).<\/li>\n<\/ul>\n<p align=\"justify\">Dominic Rodrigues, Vice Chair of the Company\u2019s Board of Directors, said, \u201cPatients who present with in-transit melanoma lesions suffer from a rare disease that is a serious, life-threatening condition with no approved therapies. No drug therapies provide the rapid, sustained reduction of tumor burden, with low toxicity, that investigational drug product PV-10 does. Injection of lesions with PV-10 is globally recognized as a treatment option for in-transit melanoma patients in clinical practice guidelines, including those for Australia<sup>a<\/sup>, Canada<sup>b<\/sup>, Europe<sup>c<\/sup>, and the U.S.<sup>d<\/sup>\u201d<\/p>\n<p align=\"justify\">Mr. Rodrigues added \u201cGiven the high percentage of in-transit melanoma lesions that achieve complete response from typically one or two PV-10 injections, and its established safety profile, we believe there is a role for PV-10 in the treatment of in-transit melanoma lesions for those patients who are not candidates for systemic drug therapies.\u201d<\/p>\n<p align=\"left\">\n        <strong>About PV-10<\/strong>\n      <\/p>\n<p align=\"justify\">Intralesional (IL) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death within hours of tumor injection, and induce tumor-specific reactivity in circulating T cells within days.<sup>1,2,3<\/sup> This IL PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB).<sup>4<\/sup> In CB-refractory advanced cutaneous melanoma, IL PV-10 may restore disease-specific T cell function, which may also be prognostic of clinical response. IL PV-10 has been administered to over 450 patients with cancers of the skin and of the liver. It is administered under visual, tactile or ultrasound guidance to superficial malignancies, and under CT or ultrasound guidance to tumors of the liver.<\/p>\n<p align=\"left\">\n        <strong>About Rose Bengal Disodium<\/strong>\n      <\/p>\n<p align=\"justify\">RBD is 4,5,6,7-tetrachloro-2&#8242;,4&#8242;,5&#8242;,7&#8242;-tetraiodofluorescein disodium, a halogenated xanthene and Provectus\u2019 proprietary lead molecule. Provectus&#8217; current Good Manufacturing Practices (cGMP) RBD is a proprietary pharmaceutical-grade drug substance produced by the Company&#8217;s quality-by-design (QbD) manufacturing process to exacting regulatory standards that avoids the formation of uncontrolled impurities currently present in commercial-grade rose bengal. Provectus&#8217; RBD and cGMP RBD manufacturing process are protected by composition of matter and manufacturing patents as well as trade secrets.<\/p>\n<p align=\"justify\">An IL formulation (i.e., by direct injection) of cGMP RBD drug substance, cGMP PV-10, is being developed as an autolytic immunotherapy drug product for solid tumor cancers.<\/p>\n<p align=\"justify\">IL PV-10 is also undergoing preclinical study for relapsed and refractory pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma.<sup>5,6<\/sup><\/p>\n<p align=\"justify\">A topical formulation of cGMP RBD drug substance, PH-10<sup>\u00ae<\/sup>, is being developed as a clinical-stage immuno-dermatology drug product for inflammatory dermatoses, such as atopic dermatitis and psoriasis. RBD can modulate multiple interleukin and interferon pathways and key cytokine disease drivers.<sup>7<\/sup><\/p>\n<p align=\"justify\">Oral formulations of cGMP RBD are undergoing preclinical study for relapsed and refractory pediatric blood cancers, such as acute lymphocytic leukemia and acute myelomonocytic leukemia.<sup>8,9<\/sup><\/p>\n<p align=\"justify\">Oral formulations of cGMP RBD are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers.<\/p>\n<p align=\"justify\">Different formulations of cGMP RBD are also undergoing preclinical study as potential treatments for multi-drug resistant (MDR) bacteria, such as Gram-negative bacteria.<\/p>\n<p align=\"justify\">Topical formulations of cGMP RBD are also undergoing preclinical study as potential treatments for diseases of the eye, such as infectious keratitis<\/p>\n<p align=\"justify\">\n        <u>Tumor Cell Lysosomes as the Seminal Cancer Drug Target<\/u>\n      <\/p>\n<p align=\"justify\">Lysosomes are the central organelles for intracellular degradation of biological materials, and nearly all types of eukaryotic cells have them. Discovered by Christian de Duve, MD in 1955, lysosomes are linked to several biological processes, including cell death and immune response. In 1959, de Duve described them as \u2018suicide bags\u2019 because their rupture causes cell death and tissue autolysis. He was awarded the Nobel Prize in 1974 for discovering and characterizing lysosomes, which are also linked to each of the three primary cell death pathways: apoptosis, autophagy, and necrosis.<\/p>\n<p align=\"justify\">\n        <u>Building on the Discovery, Exploration, and Characterization of Lysosomes<\/u>\n      <\/p>\n<p align=\"justify\">Cancer cells, particularly advanced cancer cells, are very dependent on effective lysosomal functioning.<sup>10<\/sup> Cancer progression and metastasis are associated with lysosomal compartment changes<sup>11,12<\/sup>, which are closely correlated (among other things) with invasive growth, angiogenesis, and drug resistance<sup>13<\/sup>.<\/p>\n<p align=\"justify\">RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupting the lysosomes and causing the cells to die. Provectus<sup>2,14<\/sup>, external collaborators<sup>5<\/sup>, and other researchers<sup>15,16,17<\/sup> have independently shown that RBD triggers each of the three primary cell death pathways: apoptosis, autophagy, and necrosis.<\/p>\n<p align=\"justify\">\n        <em>Cancer Cell Autolytic Death via RBD:<\/em> RBD-induced autolytic cell death, or death by self-digestion, in Hepa1-6 murine hepatocellular carcinoma (HCC) cells <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sfLm2-6Cwok_ubydCya2Lrz-u9gWV9tukZ-HynOD2zwl6TQLrhkrzB3bWsypmDreB2mX0K99AkF3HYQO0fPZ23tpvxVtSHKvB-FGjMs9bRa8CAjH6pHBjBXKaQ2_Of_a4QcTVgC-cSaMIcSRUl4m0LFMM0x4yq7BAMGQFU6e0TlmFIlNIAxzmFGdjabT2g8oU4nvQwe4fIvMDF7lxpos6g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>can be viewed in this Provectus video of the process<\/u><\/a> (ethidium homodimer 1 [ED-1] stains DNA, but is excluded from intact nuclei; lysosensor green [LSG] stains intact lysosomes; the video is provided in 30-second frames, with a duration of approximately one hour). Exposure to RBD triggers the disruption of lysosomes, followed by nucleus failure and autolytic cell death. Identical responses have been shown by the Company in HTB-133 human breast carcinoma (which <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sfLm2-6Cwok_ubydCya2Lrz-u9gWV9tukZ-HynOD2zwl6TQLrhkrzB3bWsypmDretoM6rY8HyyjGcp-v4fGr5MzC9Xr90jqfOp7ro_HLCX66xvwOHZZP4sS-szDZCMXfVnb1SwR2HQDonin0cU7KbSFeZlm8oUphcx1LMqjtBp74lm2hG9xnwNqDThTay671HN5V8tJWfBy_35OQm16PCQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>can be viewed in this Provectus video of the process<\/u><\/a>, with a duration of approximately two hours) and H69Ar human multidrug-resistant small cell lung carcinoma. Cancer cell autolytic cell death was reproduced by research collaborators in neuroblastoma cells to show that lysosomes are disrupted upon exposure to RBD.<sup>5<\/sup><\/p>\n<p align=\"justify\">\n        <em>Tumor Autolytic Death via RBD:<\/em> RBD causes acute autolytic destruction of injected tumors (via autolytic cell death), mediating the release of danger-associated molecular pattern molecules (DAMPs) and tumor antigens; release of these signaling factors may initiate an immunologic cascade where local response by the innate immune system may facilitate systemic anti-tumor immunity by the adaptive immune system. The DAMP release-mediated adaptive immune response activates lymphocytes, including CD8+ T cells, CD4+ T cells, and NKT cells, based on clinical and preclinical experience in multiple tumor types. Mediated immune signaling pathways may include an effect on STING, which plays an important role in innate immunity.<sup>9<\/sup><\/p>\n<p align=\"justify\">\n        <u>Orphan Drug Designations (ODDs)<\/u>\n      <\/p>\n<p align=\"justify\">ODD status has been granted to RBD by the U.S. Food and Drug Administration for metastatic melanoma in 2006, hepatocellular carcinoma in 2011, neuroblastoma in 2018, and ocular melanoma (including uveal melanoma) in 2019.<\/p>\n<p align=\"justify\">\n        <u>Intellectual Property<\/u>\n      <\/p>\n<p align=\"justify\">Provectus\u2019 IP includes a family of US and international (a number of countries in Asia, Europe, and North America) patents that protect the process by which cGMP RBD and related halogenated xanthenes are produced, avoiding the formation of previously unknown impurities that exist in commercial-grade rose bengal in uncontrolled amounts. The requirement to control these impurities is in accordance with International Council on Harmonisation (ICH) guidelines for the manufacturing of an injectable pharmaceutical. US patent numbers are 8,530,675, 9,273,022, and 9,422,260, with expirations ranging from 2030 to 2031.<\/p>\n<p align=\"justify\">The Company&#8217;s IP also includes a family of US and international (a number of countries in Asia, Europe, and North America) patents that protect the combination of RBD and CB (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 agents) for the treatment of a range of solid tumor cancers. US patent numbers are\u00a09,107,887,\u00a09,808,524, 9,839,688, and\u00a010,471,144, with expirations ranging from 2032 to 2035; US patent application numbers include 20200138942 (i.e., 16\/678,133), <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TlvmFXXLA8KPQ8do0LuGzwU7Bcp3rxAqOky2yg4PbE8M8-i66pgT7kPW7S-7wE-32UXPrmFeLeezqcO7JXTQuuFZyh5qtDG0zrwPFnT5ICnZi60gaZDq07aRgEZRQuVOUTVdlk2faOkxPtitBg1uLDc9IhszTPsFWYhPOmT-5ok=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>which has been allowed<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>About Provectus<\/strong>\n      <\/p>\n<p align=\"justify\">Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on an entirely- and wholly-owned family of small molecules called halogenated xanthenes. Information about the Company\u2019s clinical trials can be found at the National Institutes of Health (NIH) registry, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2UHEe-e13thpFvlKh7x8kOT-TUiudv590Q9pwhjXS6ZrV8D83HydkbmDEnmB6ThbtJYKvUCMTgsMKAhQ4cqNW33sAHKOJYrwfCYQT6D6XzE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.clinicaltrials.gov<\/u><\/a>. For additional information about Provectus, please visit the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qJMOqeVwD8nTHjm7MRGAXqaqCthtQbTlUgmA29jl_J6Z17y-TfkfTHS7uh31tGzMnQtqAQ-blfa2W8q2ycYlKIPP_GVibBleor78GZPFBfA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.provectusbio.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>References<\/strong>\n      <\/p>\n<p align=\"justify\">a. Cancer Council Australia, Clinical practice guidelines for the diagnosis and management of melanoma: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rc0e7qehOakQMM_bc2cyq-9mX4fTWDsnoLrbw2N83GCBILT8xLnI-RVbwPvZIRCv9aRjZnZ-Jv8PPKTFj3YOA_uCef4VFT2RmGvCsud7nhSpZpTQy40Y6Mha_jfH7vhKKIz1vLve0Qmj4sU5_Ri9NI25wcfGtCy1oS39XnFdSwq8ivxD-xUN6S0z_y02eYVHe0FvistJr5tSMK-4Eti5YtW0oXdwC4cJ6AKS3rqh4zy7PguYFYPmhbNg3xdLcjJT3L3VpFRSI85vL9dX0P--WC2Owm_afhNzYDPeHUUKoLQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Treatment of satellite and in-transit metastases<\/u><\/a> (May 2018)<\/p>\n<p align=\"justify\">b. Alberta Health Services, Clinical Practice Guideline: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M4QYIGIzO1FHz2kc1Vr-6pEE3Q1fqs71-gL1ZYfFXfle8hK7j17MSne-mRbl5xCS6viflDlGWJ34XX8wo9AbXtl5qiLdEEkY-Pk3ISlohCbis6Bd80bwynpsvJGhMDDpbYiQKa1s-5NPQlQqOstWOynS9R2IhWS0Ce4h-xIieVpL7tPZVL6DrgA7LPZoGplln3IeWB6Spaz0b11_YzWvlJ1vhaqcm22dvcWHqt84at0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Management of In-Transit Disease<\/u><\/a> (June 2019)<\/p>\n<p align=\"justify\">c. ESMO Guidelines Committee: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NgET-i3mwWSZ53x9SKTMyL5C3eWCTOcKolacp28fdcDHsXlSkBhhHEA6MgFUKVdrpGS5BrrbVHfe1CRTZFC6KzLG4g2xxKJEN5qIPTqum1hlvAFcItt7po97rf5yKsi6M1X1mdHPmQp6NGuskJA2tSWWjxusdqhs1lR808pHqbTJMyxt2GZ-gMRuhnlqdtBvOX9XgYrcpi7tnK2RskTxfx4GbpkBvI1GualVa-M7YzROyjpDpJ30eDMUFc2RwxsA\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>ESMO consensus conference recommendations on the management of locoregional melanoma<\/u><\/a> (November 2020)<\/p>\n<p align=\"justify\">d.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8BiKSBe5CCVhHSv-Z5XvPHwpaPi42F6gTO401C6rc7siZbQPlYBEHK2l4_fhiclAIefxMjVs8A_Wbb0XpEmNzjW0h7jTbADNgQW576wYt1s2jiatgQrzMWia5jMl4fXn0G-NB5ZPRQ8eDyC-J3oIqT8w4R-dqPZ7FaPK2qMjnSPVYVBrAl1KlE-YbDLeVZxm\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>NCCN Guidelines for Cutaneous Melanoma<\/u><\/a> (February 2021)<\/p>\n<p align=\"justify\">1. Wachter et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a5sz4d_lBXQfsa-pDaGqgK4U1fqsBzMFKahT2idms4QxHEi4JJHGtLMrKCT6FiUW2z8iKdIUOAFLMIeSx0YgLNTEwlkNFVwsdALhS0Ee81wHLGj6EGJ0Edjq1EfCHTwahIUz1VUNZaWBTASZlilnR7QyrYVWbLiXcPZVUbJJZvogrWEf8lzKTLpbuXflcBLrXDKJ516DuxKmXrJOHKYbDWNpL85Ru4pRf5RnbuZhoGCpLe3MFL2kOgnD7-UistfS\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Functional Imaging of Photosensitizers using Multiphoton Microscopy<\/u><\/a>. <em>Proceedings of SPIE<\/em> 4620, 143, 2002.<\/p>\n<p align=\"justify\">2. Liu et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TbovqCnkXeu1EFNXZlj6PqzV3IvlmeHGqS6OZMUCmrVOwWPOG1Uzy3Fj9mLJgPkJxAgCBj87YzoJUQPu0FkSTgJILym_GXYysF7t0lRN_DVr9XeLOFobXW8xQDwnk7nyeF3pbRCk6K8WWHA4IDjs84mHg8J65xzfbBZhBpTJaU6e3NGNZBdeBtVLq25wvApSfOAneHNTOt4WGVLjq2wezgzkvFlIeMVdXX3hYI6WHBgeskYlh_Uy1cRiuTj_s74xQI2sDnMvy81-lSuHOeD0FC8qrauRXva09KNOa6DICxgCOBBR_IyKT2fgBng8-WPKok01fVFPmBVYy-cVruPUBBviMa8fT8WBY-gpLXojUSM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1<\/u><\/a>. <em>Oncotarget<\/em> 7, 37893, 2016.<\/p>\n<p align=\"justify\">3. Qin et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IWKAf0-gMTmSd1ykVC6GM32qc7gpEcCsHgKkRteGZDijdVo2PI0QMfak6WD4ovjwMjPEm9b2zMShsvNtO9tAtAZHkhNB0Tc83yzN34TzYOT6-HxHFgnw_ELmmBz1LuonJfSFF6vCgGJFqgQV8NB44bcev2jfguC2EH8FwmeC7XSS5ePyauuYxWoFTOyEwk-uTW0PGUTAsQo3AQlKZBvJivad-2eMkCa-sahmw6U3oB38lVvQJhyLxw73lK2hC2wF\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death<\/u><\/a>. <em>Cell Death and Disease<\/em> 8, e2584, 2017.<\/p>\n<p align=\"justify\">4. Liu et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qd0QNHuGw5vrSm4SsGqXGeJhAg4WZzhv9xjuRP0xZL35ILCyRYn_4aCOxSGf3voIuP0IbIrLoDh1BBnLHJeA5uQusgLTOG5DsW4bEJXoGBTmfYqFeBWep-a6-dDZJLHTUOosXsnxgVX9H6asniY9REyd0VCsHdl77H8JUa6e5xOQjRN1Hkn6QeRqZbL7wz51vQbFRMHLT0Euxr46Hrl4hhBDHVqpzLyuII3aOFKOcdpt-ZTYIrJoOitKOBbr688vjV1WjeIQlKUoIZW2VeF-mIMVzKsII80D1N0aivRzGzhDncD-c20nqxbuy-pn6TvU\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1\/PD-L1 pathway in a murine melanoma model<\/u><\/a>. <em>PLoS One<\/em> 13, e0196033, 2018.<\/p>\n<p align=\"justify\">5. Swift et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qOetbuEdbbSBPXPN5u0a605Tho958l4YNkByjR844K00fes7vEje9TzLcjt05GgMHt9d_x7m53IX_btC5Drw7_PQ4TotJ-zf5BuYXhaxhv5oJTRYKdPGH-Ya7CbL0i5z3cE2s30DVTfbs5Ib1BgbnZEHjyq8H7gzzLp48LCyLyCOe04r99xB2omGM1j4kepfao-ZjawmPf21CcCMHvO07C5SW8SOKrapDrebRMmyMdJ6k3mV5seS-Ro77iHA5GEMzIyjB--86A4ppRFKkZzES44n_Ya4DmuwSVLR_75isW6MQMZNDfjXd3ZJOEDOiSyFzxgy5dvR0dJuIXkFW5sz3Wb5PfdGQKhRg94h6khALes0h4bB3JUr5bRMmUDB0xx5\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Potent <\/u><em><u>in vitro<\/u><\/em><u> and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma<\/u><\/a>. <em>OncoTargets and Therapy <\/em>12, 1293, 2019.<\/p>\n<p align=\"justify\">6. Swift et al. <em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U59C9ZekIunXG_GqKy_HqRyDlSzPMhcWfLhBnKhivE-st7em3l4U2DXKk39GCAks8MtvaF2S2NATT_yLWmIoQgzm9reQn-XzC0LZDhcFgJc8jTFSL-pAkAq8e7_su-56-RBcJvKWh27OqH8EDAEFyzXWbSMqP4rs1qf7TnrMWbjvAWze98UkCw_-BS5XGI8jaLXv0u6YdXdkCWXNoGiIKVuItgOt28IVcxdOeYIdvahsAoVLsWP_vu4jdDOYsoN8P08kmht1AZ4ia1GKb739gWxL9EuAvTIlGKThKd1iWPM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>In vitro<\/u><u> and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors<\/u><\/a><\/em>. 2018 ASCO Annual Meeting, <em>J Clin Oncol<\/em> 36, 2018 (suppl; abstr 10557).<\/p>\n<p align=\"justify\">7. Krueger et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8TNypHJf2hyhvzeKIPBcIPocwkhvH6BSGd-FSy39AH3YglPBjhRkXvbXa0zxOHWgECM9Mn1kNzzt1h_TaPJg5BrcuKUkDRSxEkzrhb9ta3ZzND9ORroUGwD-FEdbRk8eMSVmOAxMfvp67_ZzW8_1JHuwSGnmdNgHZ9MZkYvHRRTt1DTQ75fzRf-CxxFNG5xkXcR_5CEfojD7GibD-rarb_sLQZNTApGJyFWcTd_Ws1cTYgQ0Bdc1F3p6t1ghF-J1\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Immune Modulation by Topical PH-10 Aqueous Hydrogel (Rose Bengal Disodium) in Psoriasis Lesions<\/u><\/a>. Psoriasis Gene to Clinic, 8<sup>th<\/sup> International Congress, <em>Br J Dermatol <\/em>177.<\/p>\n<p align=\"justify\">8. Swift et al. <em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fbz8fpBAxzyzqj09klxRipmDn5KJPyAfqsiBJfpxAeJtKY7HW78gngJyrXjEYriHUK9OOfd9yZ0BxzK_Gqbe2PEpehXsjPD6uyOkHiW_IPGGBrOJylHwPlK2SEzpOIUGBfmPbLZASLj0rPLcNuvhYtRSyz945QzWeH5dH0hxP8KXm0B8P8jMX22Zqgz209KevfDdWbVZMphJg6LXWRYK9CcabKhFBw2k44OLiUzloDPGEAK_bXHvoyMvGpULJ3RXZfdn3xjM6WNm9624mgcSYA4ni8BIYrROZ0kV4RVMLgmhoiCKoXP8nSAz_bFNlj_hZHapfyKNwcT2WNnWZ_qdZg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>In Vitro<\/u><u> Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia<\/u><\/a><\/em>. 2018 ASH Annual Meeting, <em>Blood<\/em> 132, 2018 (suppl; abstr 5207).<\/p>\n<p align=\"justify\">9. Thakur et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-HWyraCYCh1sR7UX-6-EQ8E2GXDnXXmIc7ztcMmiIcHk_WzscU9FHyjBRn6kT6fiFRnBTxWJkntirdTEQls1np9XrzCnhS6QCMP2zh3tCzcA0IsnLHMCdGyfOfHsDQvsFGjfhFwGUPM4CYQCYOXZlkA4yAjxEajgZeAHzELk6ma4_k6ijlHRe3bXT-OZNF7Jt__8wupebCdpR7Y1MsNJhZtsC8MozlBF0caSGbDh80TtY69ozjuCjUtEDQEsqtgoMZ5EoanQ8gj-ZYdAnwly2y3XShBIyhi_0YEfKBUflULrzENl4PM092jqRQYlMkeN\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Association of heat shock proteins as chaperone for STING: A potential link in a key immune activation mechanism revealed by the novel anti-cancer agent PV-10<\/u><\/a>. 2020 AACR VAM II, (abstr 5393).<\/p>\n<p align=\"justify\">10. Piao et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UI7c6XpgCTjUE0AuWpCNZBbR2Lg8Knk3Nf_X-YDsHonWkSQ0BPj2qYj3qFbZ1lmPDasuaakEXQNPJOE1C5tgnXLNH6Sm2T9v5uOqMRgJEzpOcfhrDmyS4S7ONphd19KxuJa29VeBHq1bMYKnDiOW3g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Targeting the lysosome in cancer<\/u><\/a>. <em>Annals of the New York Academy of Sciences<\/em>. 2016; 1371(1): 45.<\/p>\n<p align=\"justify\">11. Nishimura et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qw2P0jCTHB8S66PXZSkQRhiHte4UYE89i1BZ13rC1Gs5RBzppJhwShIrUw_YvOGtmolWJ7HZrZQql0ykKZafrYilHC3hwDwOGa5eGCQyAo4Aq4qqRAbdDATgwkMHbDOmD6zSQICoUEyZI08GS_pd_jTUUeVCdYxuXsIIgr-HFXP28ul4LD0xc5T1Cw3rTW4EaFBROt2tyJ890MZjbFYgpIuagYaWAstwW-trpVZD8f0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Malignant Transformation Alters Intracellular Trafficking of Lysosomal Cathespin D in Human Breast Epithelial Cells<\/u><\/a>. <em>Pathology Oncology Research<\/em>.\u00a01998; 4(4): 283.<\/p>\n<p align=\"justify\">12. Gocheva et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JiuO1Qr_iJO2HJ1ms72UCNJrUMSFk2ElRFIo7plsEW-TSVR8qZgnhHDrVx7Mcmvnz_G-b5f6UkVN8w9_eHWG9SH8DDcRz_wd8-UkXdS_Q7Zp6ki6HsME7aNyzC9-fRD-zL75c_JXetUQkT_83bM2RZrLcMV_ElNmqQAFnB39JWoaMKcM32xXdd7eCO46SCm8l-tun5VpugYXPWg-bJ0kyA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Distinct roles for cysteine cathepsin genes in multistage tumorigenesis<\/u><\/a>. Genes &amp; Development. 2006; 20(5): 543.<\/p>\n<p align=\"justify\">13. Fehrenbacher et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CcfseFCVBbd7nZKr3NRfqyW2M7rBFz4jjxsbEQ2Q55F8JWn5M66n-r9RYfODGIkzsn7QH1lFC4U1s_c2arVIbW_VEBIukj4HQMMKpJWQSWYf4-bV0oFDopcuMgWp1HydTwP1KuPh5OmPKPTbw1eYHz2fyIDUkFK2df89pTS4z7U=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Lysosomes as Targets for Cancer Therapy<\/u><\/a>. <em>Cancer Research<\/em>. 2005; 65 (8): 2993.<\/p>\n<p align=\"justify\">14. Wachter et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yHNDs4x_KryNWG9fQiyY000V4_rmMNajuDKsOVjyuAa31K7qNQRpUM_3QOggKRehww29i5_4VuFlaYdIG51bQ9R9c3lFJFfbt-pMPcd_aHx0vao7JKo9epnhcZPUz4-ucwc4wOHzr_0fYqy_pMb3coUhCK9hKMFtHcL6cNnuee20PiT-FDNTXvsJKGceVBK1vXgMZ0d6MGI6W-IT06yVb18HpL7MRFcoSV4I86aYuguSx-19ezw5qMJQcVBTGKpa766Lo-muJJ9F5GVf8DMv-w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Imaging Photosensitizer Distribution and Pharmacology using Multiphoton Microscopy<\/u><\/a>. <em>Proceedings of SPIE<\/em> 4622, 112, 2002.<\/p>\n<p align=\"justify\">15. Koevary. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FGTyTEoLXDKiQR0tMeC4ipzjqK7T9vLMt7kOWXZvwshS-GupvQmTGbWcnBxTQbIhLXsXMeQHKRtAWBjLH1ypL8B6rcCzvBa4wX7cWFcLXsOBXwb2o_Mb68gvOVNDqwEBIkaIfX0bDuR5u58gnMMgfdcvwGZERm-cbj-YENvwacNOYRzR6PKIpQc3AG3svtio\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Selective toxicity of rose Bengal to ovarian cancer cells in vitro<\/u><\/a>. <em>International Journal of Physiology, Pathophysiology and Pharmacology<\/em> 4(2), 99, 2012.<\/p>\n<p align=\"justify\">16. Zamani et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VavgJDLGsQWsTjoAy-M4sfX_0DWrxqhTyVJI3cuykdEqlWLM1QIm8mVSxYCY7bvJvrXukL1g-74b-iwsC7YwWmUc9v38XGUhhpVRPsaATGCbImw0L6lL2YY9weV2qD5PCMAE0MNbRWcKkAvvg6c2hHhjc1MTxTvnorIi6rVh0PltV9g5NNFxxNRbXnImdU6aFG-okBpY7iQwodaMA8Gm4uWT0ZsP1yjkcN8Y3H6gL9C2BDmbY6NrOK2e-W50BppWa3DsEV2auXGMwlV12luH5J5D_jo8-M_qCEM33qDZrmY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Rose Bengal suppresses gastric cancer cell proliferation via apoptosis and inhibits nitric oxide formation in macrophages<\/u><\/a>. <em>Journal of Immunotoxicology<\/em>, 11(4), 367, 2014.<\/p>\n<p align=\"justify\">17. Luciana et al. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VavgJDLGsQWsTjoAy-M4sYZW-EbndJFWgCoDQPxtD1nwFSk4DPgTbdV9RrTPtq-lO1pd5gdBB14-ju_5BULPfZW7zmUjYEBznCteIfFQWJs5KaGcvhOvWdR2lE_G4ABuEIaKHhQ-eHQpNaGOQnCwrpn7Pl6G1GKG59bAaO_69rfUrRf1mc7d0RV-4eBkgdAo\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Rose Bengal Acetate photodynamic therapy-induced autophagy<\/u><\/a>. <em>Cancer Biology &amp; Therapy<\/em>, 10:10, 1048, 2010.<\/p>\n<p align=\"left\">\n        <strong>Trademarks<\/strong>\n      <\/p>\n<p align=\"justify\">PV-10<sup>\u00ae<\/sup> and PH-10<sup>\u00ae<\/sup> are registered trademarks of Provectus, Knoxville, Tennessee, U.S.A.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>FORWARD-LOOKING STATEMENTS:<\/em><br \/>\n        <\/strong><br \/>\n        <em> The information in this press release may include \u201cforward-looking statements,\u201d within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as \u201cseek,\u201d \u201canticipate,\u201d \u201cbudget,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cproject,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ctargeting,\u201d \u201cintend,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cshould,\u201d \u201cbelieve,\u201d and similar words suggesting future outcomes or statements regarding an outlook.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The safety and efficacy of the agents and\/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Risks, uncertainties, and assumptions include those discussed in the Company\u2019s filings with the SEC, including those described in <\/em><br \/>\n        <em><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xkhl6C7CQbC1jLwxN_D4KfAvLE4ujBTgVpxa4GuQOE6c6pMBTrSmSeU6JVBlFMHdczTsiBVFGIJvdR_f1ekXy1M0NsDs8TcgzNDpsbxVIKVc0AJtnJxEnNMgDNnjalmBZNpbhbnVm0ra7r8fSaOi-7FD7hilfOeq9Vm6Zmj_iAJ0hE2IzoG42SWjm2mhUMB1ykMNFjzarUuDQNF8RnqGyOjGF99g9qgaZl23Cji3fFmYAjUPlzuOZooHOAO3eqbe\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n            <u>Item 1A of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2020<\/u><br \/>\n          <\/a><br \/>\n        <\/em><br \/>\n        <em> and <\/em><br \/>\n        <em><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_9aqvGhaS_rABw1JAEgDqI-ogPWozaysaAB0PgBMymqQmgMDs04sxXdbGPE5vdhR3lZCGsfWiXucu7BrzXvY_SKspQcPPlDLtfEGSdwdAAq1HgZqDH9FNZpcRMQ_ed_NL-G0ilmVRMqFjY20O6KcQsNMtA86LXoaNZDs3qwvNgyhaQQhN6vPlKsxOb8wWEa4LBQ2cYFycBym5qVh2dsRmsYl7kqUWMlYXNK-9fsb1AU4LqistVYZtPuB5oJBdtO4\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n            <u>Provectus\u2019 Quarterly Report on Form 10-Q for the quarter ended September 30, 2020<\/u><br \/>\n          <\/a><br \/>\n        <\/em><br \/>\n        <em>.<\/em>\n      <\/p>\n<p align=\"center\">###<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Provectus Biopharmaceuticals, Inc.<br \/>Heather Raines, CPA<br \/>Chief Financial Officer<br \/>Phone: (866) 594-5999<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4975c3f5-b11b-4d38-9ce6-019e0b56ee9d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>46% complete response of patients at Melanoma Institute Australia Fifth published study of in-transit melanoma lesion treatment with single-agent PV-10 26-50% complete response (52-86% overall response) in these studies KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) &#8212; Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-transit melanoma (ITM) patients who received intralesional (aka intratumoral) PV-10 under a Provectus-sponsored expanded access (aka compassionate use) program (EAP). The Melanoma Research article, entitled \u201cTreatment of in-transit melanoma metastases using intralesional PV-10,\u201d detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016. The article may be accessed at: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-468313","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"46% complete response of patients at Melanoma Institute Australia Fifth published study of in-transit melanoma lesion treatment with single-agent PV-10 26-50% complete response (52-86% overall response) in these studies KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) &#8212; Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-transit melanoma (ITM) patients who received intralesional (aka intratumoral) PV-10 under a Provectus-sponsored expanded access (aka compassionate use) program (EAP). The Melanoma Research article, entitled \u201cTreatment of in-transit melanoma metastases using intralesional PV-10,\u201d detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016. The article may be accessed at: &hellip; Continue reading &quot;Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-31T11:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions\",\"datePublished\":\"2021-03-31T11:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/\"},\"wordCount\":2342,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/\",\"name\":\"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==\",\"datePublished\":\"2021-03-31T11:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/","og_locale":"en_US","og_type":"article","og_title":"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions - Market Newsdesk","og_description":"46% complete response of patients at Melanoma Institute Australia Fifth published study of in-transit melanoma lesion treatment with single-agent PV-10 26-50% complete response (52-86% overall response) in these studies KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) &#8212; Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-transit melanoma (ITM) patients who received intralesional (aka intratumoral) PV-10 under a Provectus-sponsored expanded access (aka compassionate use) program (EAP). The Melanoma Research article, entitled \u201cTreatment of in-transit melanoma metastases using intralesional PV-10,\u201d detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016. The article may be accessed at: &hellip; Continue reading \"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-31T11:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions","datePublished":"2021-03-31T11:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/"},"wordCount":2342,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/","name":"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==","datePublished":"2021-03-31T11:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTEyMCM0MDk5MzQ1IzUwMDAyODUwNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/provectus-biopharmaceuticals-announces-publication-of-australian-compassionate-use-patients-treated-with-pv-10-immunotherapy-for-in-transit-melanoma-lesions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10\u00ae Immunotherapy for In-Transit Melanoma Lesions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/468313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=468313"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/468313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=468313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=468313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=468313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}